Novel agents in immuno-oncology headline the drug center’s upcoming goal dates, while gene therapies make up most of the biologic center’s workload.

A third US biosimilar to Regeneron’s Eylea has won approval. However, enthusiasm is muted at this stage as biosimilar sponsors, including latest recipient Formycon, continue to battle against court-issued blockades.

Gain Therapeutics aims to offer a disease-modifying treatment for Parkinson’s patients with GCase mutations. The company’s promising data and platform face competition from notable rivals.

One of the self-proclaimed frontrunners in the pembrolizumab biosimilar race, Formycon, has initiated the first clinical trial for its FYB206 candidate. Meanwhile, Celltrion submits a Phase III trial application to the FDA, expecting “limitless” sales potential for its CT-P51 version.